摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,4-二氧代-4-(2-噻吩)丁酸乙酯 | 36983-36-5

中文名称
2,4-二氧代-4-(2-噻吩)丁酸乙酯
中文别名
——
英文名称
ethyl 2,4-dioxo-4-(thiophen-2-yl)butanoate
英文别名
ethyl 2-thenoylpyruvate;ethyl 2,4-dioxo-4-(2-thienyl)butanoate;ethyl 2,4-dioxo-4-thiophen-2-ylbutanoate
2,4-二氧代-4-(2-噻吩)丁酸乙酯化学式
CAS
36983-36-5
化学式
C10H10O4S
mdl
——
分子量
226.253
InChiKey
GCCFYXYKJZUHMI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    34°C

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    15
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    88.7
  • 氢给体数:
    0
  • 氢受体数:
    5

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2934999090

SDS

SDS:7b1a2f632cda52030b7b99bb05bb0a9e
查看
Name: Ethyl 2 4-dioxo-4-(2-thienyl)butanoate 90+% Material Safety Data Sheet
Synonym: Ethyl 2-thenoylpyruvat
CAS: 36983-36-5
Section 1 - Chemical Product MSDS Name:Ethyl 2 4-dioxo-4-(2-thienyl)butanoate 90+% Material Safety Data Sheet
Synonym:Ethyl 2-thenoylpyruvat

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
36983-36-5 Ethyl 2,4-dioxo-4-(2-thienyl)butanoate 90+% unlisted
Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Moisture sensitive.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 36983-36-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 34 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10O4S
Molecular Weight: 226

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 36983-36-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 2,4-dioxo-4-(2-thienyl)butanoate - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 36983-36-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 36983-36-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 36983-36-5 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,4-二氧代-4-(2-噻吩)丁酸乙酯草酰氯 、 lithium hydroxide monohydrate 、 盐酸羟胺三乙酰氧基硼氢化钠碳酸氢钠戴斯-马丁氧化剂溶剂黄146N,N-二甲基甲酰胺 作用下, 以 四氢呋喃甲醇乙醇二氯甲烷 为溶剂, 反应 40.0h, 生成 N-(5-((3R,4S)-3-carbamoyl-4-cyanopiperidin-1-yl)pentyl)-5-(thiophen-2-yl)isoxazole-3-carboxamide
    参考文献:
    名称:
    [EN] ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF
    [FR] COMPOSÉS D'ISOXAZOLE CARBOXAMIDE ET LEURS UTILISATIONS
    摘要:
    提供了一个化合物的化学式(I)或其药用盐,已被证明对治疗听力损失或平衡障碍有用:化学式(I),其中R1和Y的定义如下。
    公开号:
    WO2020058913A1
  • 作为产物:
    参考文献:
    名称:
    Xa因子活性位点的分子识别:阳离子-π相互作用,平面肽表面堆积和结构水的置换
    摘要:
    Xa因子是一种来自凝血级联的丝氨酸蛋白酶,是分子识别研究的理想酶,因为其活性位点具有高度的形状持久性,并具有独特的凹子口袋。我们开发了一系列非肽小分子抑制剂,这些抑制剂具有中心三环核,该核将中性杂环取代基定向到S1袋中,并将季铵离子定向到S4袋中的芳族盒中。系统地改变了取代基的种类,以研究S4口袋中的阳离子与π相互作用,S1口袋内衬的扁平肽壁上的最佳杂环堆积以及S1和S4口袋中的潜在水替代物。建立了构效关系,以揭示和量化对结合自由焓的贡献,由单原子替换或配体位置变化引起的。一系列高亲和力配体,抑制常数低至获得了K i = 2 n M,并通过蛋白质-配体复合物的X射线共晶体结构证实了其拟定的结合几何形状。
    DOI:
    10.1002/chem.201102571
点击查看最新优质反应信息

文献信息

  • ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF
    申请人:NOVARTIS AG
    公开号:US20180271837A1
    公开(公告)日:2018-09-27
    A compound of Formula (I)) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: wherein R 1 through R 3 , and L are as defined herein.
    提供了一种具有治疗听力丧失或平衡紊乱作用的化合物(I)的药物可接受盐,其中R1至R3和L如本文所定义。
  • [EN] AZAINDAZOLES<br/>[FR] AZAINDAZOLES
    申请人:GLAX0SMITHKLINE LLC
    公开号:WO2013039988A1
    公开(公告)日:2013-03-21
    Herein are disclosed azaindazoles of formula (I), (I), where the various groups are defined herein, and which are useful for treating cancer.
    这里公开了公式(I)、(I)的氮杂吲唑,其中各团簇在本发明中定义,并且用于治疗癌症。
  • MODULATORS FOR AMYLOID BETA
    申请人:Baumann Karlheinz
    公开号:US20090215759A1
    公开(公告)日:2009-08-27
    The invention relates to compounds of formula wherein the substituents are as described in claim 1 . Compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.
    该发明涉及以下式的化合物 其中取代基如权利要求中所述 。式I的化合物是淀粉样蛋白β的调节剂,因此它们可能对治疗或预防与大脑中β-淀粉样蛋白沉积相关的疾病有用,特别是阿尔茨海默病,以及其他疾病,如脑淀粉样血管病变,遗传性脑出血伴淀粉样变性,荷兰型(HCHWA-D),多梗死性痴呆,拳击性痴呆和唐氏综合征。
  • Asymmetric Hydrogenation of 2,4-Dioxo Esters: Selective Synthesis of 2-Hydroxy-4-oxo Esters and Direct Access to Chiral 2-Hydroxy-4-butyrolactones
    作者:Véronique Blandin、Jean-François Carpentier、André Mortreux
    DOI:10.1002/(sici)1099-0690(199908)1999:8<1787::aid-ejoc1787>3.0.co;2-o
    日期:1999.8
    2,4-Dioxoesters 1a–c are selectively converted into optically active 2-hydroxy-4-oxoesters 2a–c by hydrogenation with chiral rhodium-aminophosphane-phosphinite catalysts (82–88% ee) or ruthenium-bisphosphane catalysts (52–67% ee). Direct one-pot hydrogenation of 2,4-dioxoesters 1a–c to 2-hydroxy-4-butyrolactones 4a–c proceeds in high yields; catalytic activities, chemo-, dia-, and enantioselectivities
    2,4-二氧代酯 1a-c 通过手性铑-氨基膦-次膦酸催化剂(82-88% ee)或钌-双膦催化剂(52-67)的氢化反应选择性地转化为光学活性的 2-羟基-4-氧代酯 2a-c % ee)。2,4-二氧代酯 1a-c 直接一锅加氢生成 2-羟基-4-丁内酯 4a-c,收率高;催化活性、化学选择性、渗析选择性和对映选择性在很大程度上取决于底物和催化剂的性质。
  • [EN] COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE LA DÉSHYDROGÉNASE À CHAÎNE COURTE
    申请人:UNIV CASE WESTERN RESERVE
    公开号:WO2015065716A1
    公开(公告)日:2015-05-07
    Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
    调节15-PGDH活性的化合物和方法,调节组织前列腺素水平,治疗希望调节15-PGDH活性和/或前列腺素水平的疾病、疾病障碍或病况,包括本文所描述的15-PGDH抑制剂。
查看更多

同类化合物

马来酰基乙酸 顺-3-己烯-1-丙酮酸 青霉酸 钠氟草酰乙酸二乙酯 醚化物 酮霉素 辛酸,2,4-二羰基-,乙基酯 草酸乙酯钠盐 草酰乙酸二乙酯钠盐 草酰乙酸二乙酯 草酰乙酸 草酰丙酸二乙酯 苯乙酰丙二酸二乙酯 苯丁酸,b-羰基-,2-丙烯基酯 聚氧化乙烯 羟基-(3-羟基-2,3-二氧代丙基)-氧代鏻 磷酸二氢2-{(E)-2-[4-(二乙胺基)-2-甲基苯基]乙烯基}-1,3,3-三甲基-3H-吲哚正离子 碘化镝 硬脂酰乙酸乙酯 甲氧基乙酸乙酯 甲氧基乙酰乙酸酯 甲基氧代琥珀酸二甲盐 甲基4-环己基-3-氧代丁酸酯 甲基4-氯-3-氧代戊酸酯 甲基4-氧代癸酸酯 甲基4-氧代月桂酸酯 甲基4-(甲氧基-甲基磷酰)-2,2,4-三甲基-3-氧代戊酸酯 甲基3-羰基-2-丙酰戊酸酯 甲基3-氧代十五烷酸酯 甲基2-氟-3-氧戊酯 甲基2-氟-3-氧代己酸酯 甲基2-氟-3-氧代丁酸酯 甲基2-乙酰基环丙烷羧酸酯 甲基2-乙酰基-4-甲基-4-戊烯酸酯 甲基2-乙酰基-2-丙-2-烯基戊-4-烯酸酯 甲基2,5-二氟-3-氧代戊酸酯 甲基2,4-二氟-3-氧代戊酸酯 甲基2,4-二氟-3-氧代丁酸酯 甲基1-异丁酰基环戊烷羧酸酯 甲基1-乙酰基环戊烷羧酸酯 甲基1-乙酰基环丙烷羧酸酯 甲基(2Z,4E,6E)-2-乙酰基-7-(二甲基氨基)-2,4,6-庚三烯酸酯 甲基(2S)-2-甲基-4-氧代戊酸酯 甲基(1R,2R)-2-乙酰基环丙烷羧酸酯 瑞舒伐他汀杂质 瑞舒伐他汀杂质 环氧乙烷基甲基乙酰乙酸酯 环戊戊烯酸,Β-氧代,乙酯 环戊基(氧代)乙酸乙酯 环戊[b]吡咯-6-腈,八氢-2-氧-,[3aS-(3aalpha,6alpha,6aalpha)]-(9CI)